Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-06-25

Coya Therapeutics, Inc. (COYA)

CEO Arun Swaminathan was paid $2,091,007 in fiscal year 2025, ↑ up 39.7% from fiscal year 2024 (SEC filing 0001193125-26-220688 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$2,091,007 ↑
Arun Swaminathan total, FY2025
—
CEO pay percentile vs peers
—
CEO-to-median pay ratio
—
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Arun Swaminathan (Chief Executive Officer, Director), FY2025 total compensation $2,091,007 (base salary $546,000) [exec_comp, SEC accession 0001193125-26-220688, filed 2026-05-13]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

COYA's next annual pay disclosure, estimated May 13, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Arun Swaminathan$546,000$395,850$0$1,149,157$0$0$0$2,091,007
Chief Executive Officer, Director
Howard Berman436,800316,6800718,2210001,471,701
Former Chief Executive Officer, Former Executive Chairman of the Board
Fred Grossman498,160288,9330670,3400001,457,433
President, Chief Medical Officer
David Snyder442,000256,3600670,3400001,368,700
Chief Financial Officer and Chief Operating Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Arun Swaminathan$2,091,007$1,497,168—↑ +593,839
Howard Berman1,471,7012,680,268—↓ −1,208,567
Fred Grossman1,457,4331,892,438—↓ −435,005
David Snyder1,368,7001,465,084—↓ −96,384

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Coya Therapeutics, Inc.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper COYA reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against COYA
No companies currently name COYA as a compensation peer in their most recent disclosure.

This is the complete answer, not a partial one — the list is never padded.

02

Equity transactions since the proxy statement was filed

No insider equity transactions reported since the proxy statement.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Fred GrossmanOption97,6136.07—
Howard BermanOption55,8575.9—
Howard BermanOption77,2868.15—
Fred GrossmanOption33,3378.15—
Arun SwaminathanOption29,5465.9—
Fred GrossmanOption29,5465.9—
Arun SwaminathanOption12,7784.05—
David SnyderOption6,3893.85—
David SnyderOption33,3378.15—
Arun SwaminathanOption33,3378.15—
Arun SwaminathanOption167,3376.07—
David SnyderOption29,5465.9—
David SnyderOption97,6136.07—
Fred GrossmanOption14,4034.25—
Fred GrossmanOption14,3995.9—
Howard BermanOption9,1673.85—
Howard BermanOption104,5856.07—
05

Incentive-plan design — the Compensation Discussion & Analysis

Our compensation packages for the named executive officers consist primarily of base salary, annual cash bonus and a stock option grant.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultant—
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingfalse
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-25—————
20252025-06-26—————
20242024-05-08—————
20232023-06-28—————

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-25—a
20252025-06-26—b
20242024-05-08—c

a. Voting standard not stated in the filing.

b. Voting standard not stated in the filing.

c. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Dov GoldsteinIndependent · Audit (Chair) · Compensation · Nominating and Corporate Governance$63,752$0$45,270——$109,022
Anabella VillalobosIndependent · Compensation (Chair) · Nominating and Corporate Governance53,752045,270——99,022
Dieter WeinandIndependent · Audit · Compensation · Nominating and Corporate Governance (Chair)53,252045,270——98,522
Ann LeeIndependent · Audit · Compensation52,500045,270——97,770
Wilbur RossIndependent40,000045,270——85,270
Arun SwaminathanEmployee director—————0
Mark PavaoIndependent · Newly elected——————
09

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer$10,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)7,500 / 10,000 / 7,500
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$263,256
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$263,256

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Coya Therapeutics, Inc.2025Arun Swaminathan$546,000$0$1,149,157$0$2,091,007

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10d

Frequently asked questions

Who was the highest-paid executive at Coya Therapeutics, Inc. in fiscal 2025?
As disclosed, Arun Swaminathan (Chief Executive Officer, Director) was the highest-paid executive at Coya Therapeutics, Inc. in fiscal 2025, with total compensation of $2,091,007.
How much does Coya Therapeutics, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Coya Therapeutics, Inc. reported total board compensation of $263,256 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Arun SwaminathanDEF 14A2026-05-130001193125-26-220688Section “Summary Compensation Table”. As printed: 2,091,007. Filing ↗machine: r2 · c19 · span 214239–214248
2Section 01, Howard BermanDEF 14A2026-05-130001193125-26-220688Section “Summary Compensation Table”. As printed: 1,471,701. Filing ↗machine: r4 · c19 · span 217312–217321
3Section 01, Fred GrossmanDEF 14A2026-05-130001193125-26-220688Section “Summary Compensation Table”. As printed: 1,457,433. Filing ↗machine: r8 · c19 · span 223733–223742
4Section 01, David SnyderDEF 14A2026-05-130001193125-26-220688Section “Summary Compensation Table”. As printed: 1,368,700. Filing ↗machine: r6 · c19 · span 220504–220513
5Section 08, Dov GoldsteinDEF 14A2026-05-130001193125-26-220688Section “Director Compensation”. As printed: 109,022. Filing ↗machine: span 298298–298305
6Section 08, Anabella VillalobosDEF 14A2026-05-130001193125-26-220688Section “Director Compensation”. As printed: 99,022. Filing ↗machine: span 302296–302302
7Section 08, Dieter WeinandDEF 14A2026-05-130001193125-26-220688Section “Director Compensation”. As printed: 98,522. Filing ↗machine: span 303642–303648
8Section 08, Ann LeeDEF 14A2026-05-130001193125-26-220688Section “Director Compensation”. As printed: 97,770. Filing ↗machine: span 299620–299626
9Section 08, Wilbur RossDEF 14A2026-05-130001193125-26-220688Section “Director Compensation”. As printed: 85,270. Filing ↗machine: span 300963–300969
10Section 08, Arun SwaminathanDEF 14A2026-05-130001193125-26-220688Section “Director Compensation”. As printed: 0. Filing ↗
11Section 08, Mark PavaoDEF 14A2026-05-130001193125-26-220688Section “Director Compensation”. As printed: —. Filing ↗
12Section 06, 2026 voteForm 8-K2026-06-250001193125-26-282989Item 5.07 · say-on-pay result. As reported: —. Filing ↗
13Section 06, 2025 voteForm 8-K2025-06-260001193125-25-149104Item 5.07 · say-on-pay result. As reported: —. Filing ↗
14Section 06, 2024 voteForm 8-K2024-05-080001193125-24-134376Item 5.07 · say-on-pay result. As reported: —. Filing ↗
15Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
16Section 09b board cost (computed)Computed——Cash 263,256 + equity 0 + all other 0 = 263,256, summed across the director compensation table rows.machine: formula: Σ = 263,256
17Coya Therapeutics, Inc. (subject), Section 10b CEO totalDEF 14A2026-05-130001193125-26-220688CEO total compensation as printed in Coya Therapeutics, Inc.'s own proxy. As printed: 2,091,007. Filing ↗machine: r2 · c19 · span 214239–214248

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.